GEN Exclusives

More »

GEN News Highlights

Back to Item »

Alopexx, Provenance Ink $8M Deal for Anticancer Immunotherapeutic

Firms will establish company to continue development of Provenance’s Phase I-stage DI-Leu16-IL2 against hematologic cancers.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Genetic Testing for Children and Adolescents

Do you think parents should have predictive testing carried out on their children and adolescents?

More »